Traws Pharma, Inc. Common Stock (TRAW) is a publicly traded Healthcare sector company. As of May 21, 2026, TRAW trades at $1.70 with a market cap of $26.67M and a P/E ratio of -0.94. TRAW moved +3.14% today. Year to date, TRAW is +25.58%; over the trailing twelve months it is +29.60%. Its 52-week range spans $0.97 to $19.44. Rallies surfaces TRAW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Traws Pharma Raises $60M PIPE, Eyes Q2 Human Flu Trial: Traws Pharma secured up to $60M in PIPE financing (including $10M upfront at $1.673/share) to fund operations into Q1 2027 and completion of a Q2 2026 human influenza challenge trial for tivoxavir marboxil. Q1 net loss widened to $7.1M on $4.9M R&D spend and $2.0M G&A.
| Metric | Value |
|---|---|
| Price | $1.70 |
| Market Cap | $26.67M |
| P/E Ratio | -0.94 |
| EPS | $-1.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.44 |
| 52-Week Low | $0.97 |
| Volume | 3.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.73M |
| Net Income | $-19.43M |
| Gross Margin | 0.00% |
TRAW analyst coverage data. Average price target: $0.00.